Project Grant R01CA301785
- <p>The National Cancer Institute awarded the University of Hawaii at Manoa $402,401 on July 16, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on microplastics and obesity in the MEC adiposity phenotype study. Work is performed in Honolulu, Hawaii, and continues through June 30, 2028. The project was submitted in response to PAR-21-341 "Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)."</p>
- The National Cancer Institute awarded the University of Hawaii at Manoa $663,930 under the Cancer Biology Research program (CFDA 93.396) on August 1, 2026, to develop and validate novel biomarkers for predicting immunotherapy response in non-small cell lung cancer (NSCLC). The recipient will conduct two primary aims. In Aim 1, the university will create and validate a laboratory test based on an 11-gene expression signature using 200 tissue samples from NSCLC patients prior to immunotherapy...
- The National Cancer Institute awarded Centro Comprensivo De Cancer De La Universidad De Puerto Rico $591,360 on August 27, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393, Assistance Type: Project Grant) to dissect the role of inherited non-coding variants in the enhancer architecture of breast cancer. The research investigates how inherited genetic variation alters enhancer function and transcriptional regulation in breast cancer, with specific focus on FOXA1, a...
- The National Institute for Minority Health and Health Disparities awarded the University of Hawaii $644,528 on September 1, 2026, under the Minority Health and Health Disparities Research program (CFDA 93.307) to measure the impact of a Native Hawaiian community-based birth preparation program on maternal health outcomes and prenatal care engagement. The recipient will conduct a quasi-experimental cohort study of Ka Lahui O Ka Po, an established, culturally grounded birth preparation program...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Hawaii at Manoa a $402,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for research investigating neutrophilic myeloid-derived suppressor cells (PMN-MDSCs) as an immunotherapy target in hepatoblastoma. The grant, effective from May 15, 2025 through April 30, 2027, will deliver preclinical research combining innovative mouse genetic approaches with therapeutic studies to determine how...
- The National Cancer Institute awarded a Cooperative Agreement totaling $1,065,977 to Duke University on August 3, 2026, to investigate the molecular and cellular basis of ductal carcinoma in situ (DCIS) progression during active surveillance, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). Duke University will conduct a multiscale analysis of DCIS lesions and their cellular neighborhoods to identify molecular and cellular markers that distinguish high-risk from...
- The National Cancer Institute awarded the University of California, San Diego $486,094 on June 19, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to investigate weak cell adhesion as a prognostic signature and predictor of invasive breast cancer progression. The research addresses the clinical problem that low-grade and localized breast cancers such as ductal carcinoma in situ (DCIS) relapse in up to 20 percent of cases despite standard of care, affecting over...
- The National Cancer Institute awarded the University of Southern California $254,091 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support postdoctoral training in integrative cancer epidemiology. The award funds a joint training program administered by USC's Norris Comprehensive Cancer Center and the University of Hawaii Cancer Center. The program trains postdoctoral fellows for independent careers in integrative cancer epidemiology research, emphasizing...
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $135,951 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded September 4, 2025, with completion targeted for August 31, 2030. This grant supports research to enhance access to breast cancer prevention clinical trials, addressing well-documented barriers including insufficient population representation, limited awareness of...
- The National Cancer Institute awarded the University of Southern California $699,303 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify pre-diagnostic epigenetic biomarkers of colorectal cancer risk and understand epigenetic mechanisms of lifestyle and genetic CRC risk factors across multiple U.S. populations. The research will conduct a nested case-control study of 1,500 colorectal cancer cases and 1,500 matched controls drawn from the...
The National Cancer Institute awarded the University of Hawaii $555,703 on August 13, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify biological mechanisms and risk factors contributing to the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer among Asian American and Native Hawaiian/Pacific Islander (AANHPI) populations. The research addresses a clinical gap: fewer than 50 percent of DCIS patients progress to invasive cancer, yet no reliable method currently stratifies DCIS tumors by progression risk across racial and ethnic groups. Preliminary findings show disparities in DCIS progression risk among AANHPI patients, with Native Hawaiian, Filipino, and Japanese DCIS patients demonstrating elevated risk of subsequent ipsilateral invasive breast cancer compared to white patients. The study will leverage comprehensive exposure data and biospecimens from the Multiethnic Cohort and the Hawaii Tumor Registry to investigate multilevel factors contributing to racial and ethnic differences in early breast cancer pathogenesis and to identify lifestyle, sociodemographic, and tumor marker variations in AANHPI populations that may explain observed disparities. The award is a Project Grant, the assistance type. Performance occurs in Honolulu, Hawaii. The period of performance extends from the award date through July 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $555.7k | 8/13/26 |